U Mrowietz
Overview
Explore the profile of U Mrowietz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
190
Citations
3159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mrowietz U, Sumbul M, Gerdes S
J Eur Acad Dermatol Venereol
. 2023 May;
37(9):1731-1738.
PMID: 37184282
Psoriatic disease is a chronic, systemic immune-mediated inflammatory disorder comprising three major domains, skin, vascular and bone/joint inflammation. It is known for a long time that psoriatic disease is associated...
2.
Sommer R, Westphal L, Mrowietz U, Gerdes S, Augustin M
J Eur Acad Dermatol Venereol
. 2022 Jul;
36(12):e986-e987.
PMID: 35788987
No abstract available.
3.
Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Kaplan Saday K, et al.
J Eur Acad Dermatol Venereol
. 2022 Mar;
36(8):1275-1283.
PMID: 35279890
Background: Brodalumab is a monoclonal antibody that blocks multiple interleukin (IL)-17 family cytokines by binding to the shared A subunit of the IL-17 receptor. In Phase 3 trials, brodalumab provided...
4.
Shourick J, Taieb C, Seneschal J, Merhand S, Ezzedine K, Halioua B, et al.
J Eur Acad Dermatol Venereol
. 2021 Oct;
36(3):e192-e193.
PMID: 34626005
No abstract available.
5.
Reich K, Mrowietz U, Menter A, Griffiths C, Bagel J, Strober B, et al.
J Eur Acad Dermatol Venereol
. 2021 Jul;
35(12):2409-2414.
PMID: 34255891
Background: Treating to absolute treatment targets rather than relative measures such as Psoriasis Area and Severity Index (PASI)-75 is emerging as an important clinical concept included in psoriasis guidelines and...
6.
Pinter A, Mrowietz U, Volz T
Hautarzt
. 2021 Jun;
72(8):686-691.
PMID: 34189590
Systemic treatment together with radical surgical excision is the most important treatment option for all severity grades of hidradenitis suppurativa. Tetracycline in mild-to-moderate forms and clindamycin in combination with rifampicin...
7.
Mrowietz U, Dieckmann T, Gerdes S, Szymczak S, von Spreckelsen R, Korber A
J Eur Acad Dermatol Venereol
. 2021 Jun;
35(10):2027-2033.
PMID: 34076926
Background: Assessment of psoriasis is exclusively done measuring severity using somatic scores such as the psoriasis area and severity index or patient-reported outcomes such as the dermatology life quality index....
8.
Maul J, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, et al.
Br J Dermatol
. 2021 Apr;
185(6):1160-1168.
PMID: 33837519
Background: Few systematic data on sex-related treatment responses exist for psoriasis. Objectives: To evaluate sex differences with respect to systemic antipsoriatic treatment. Methods: Data from patients with moderate-to-severe psoriasis in...
9.
Langenbruch A, Mohr N, Kirsten N, Reich K, von Kiedrowski R, Stromer K, et al.
J Eur Acad Dermatol Venereol
. 2021 Mar;
35(7):1536-1542.
PMID: 33714231
Background: In the study series PsoHealth first data from 2004/05 showed a poor quality of health care for psoriasis in Germany. Most patients lacked sufficient care and only a minor...
10.
Morrison P, Suhrkamp I, Gerdes S, Mrowietz U
Br J Dermatol
. 2021 Mar;
185(3):605-615.
PMID: 33657656
Background: Dimethyl fumarate (DMF) is a treatment for moderate-to-severe psoriasis and multiple sclerosis. DMF therapy typically improves skin inflammation within the first 3 months of treatment. DMF is a prodrug...